CL2019001918A1 - Métodos para tratar infecciones bacterianas. - Google Patents

Métodos para tratar infecciones bacterianas.

Info

Publication number
CL2019001918A1
CL2019001918A1 CL2019001918A CL2019001918A CL2019001918A1 CL 2019001918 A1 CL2019001918 A1 CL 2019001918A1 CL 2019001918 A CL2019001918 A CL 2019001918A CL 2019001918 A CL2019001918 A CL 2019001918A CL 2019001918 A1 CL2019001918 A1 CL 2019001918A1
Authority
CL
Chile
Prior art keywords
methods
bacterial infections
treating bacterial
urinary tract
tract infection
Prior art date
Application number
CL2019001918A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey S Loutit
Michael N Dudley
Elizabeth E Morgan
Karen Fusaro
David C Griffith
Olga Lomovskaya
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62791302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019001918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of CL2019001918A1 publication Critical patent/CL2019001918A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2019001918A 2017-01-09 2019-07-09 Métodos para tratar infecciones bacterianas. CL2019001918A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762444238P 2017-01-09 2017-01-09
US201762513936P 2017-06-01 2017-06-01

Publications (1)

Publication Number Publication Date
CL2019001918A1 true CL2019001918A1 (es) 2020-02-14

Family

ID=62791302

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019001918A CL2019001918A1 (es) 2017-01-09 2019-07-09 Métodos para tratar infecciones bacterianas.
CL2020001886A CL2020001886A1 (es) 2017-01-09 2020-07-17 Métodos para tratar infecciones bacterianas. (divisional solicitud 201901918)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020001886A CL2020001886A1 (es) 2017-01-09 2020-07-17 Métodos para tratar infecciones bacterianas. (divisional solicitud 201901918)

Country Status (21)

Country Link
US (1) US12478606B2 (https=)
EP (2) EP3565551B1 (https=)
JP (2) JP7436206B2 (https=)
KR (2) KR102768209B1 (https=)
CN (1) CN110402139A (https=)
AU (1) AU2018205327B2 (https=)
BR (1) BR112019014089A2 (https=)
CA (1) CA3048650A1 (https=)
CL (2) CL2019001918A1 (https=)
CO (1) CO2019008575A2 (https=)
DK (1) DK3565551T3 (https=)
ES (1) ES2979266T3 (https=)
FI (1) FI3565551T3 (https=)
HU (1) HUE066805T2 (https=)
MX (2) MX390529B (https=)
NZ (1) NZ755141A (https=)
PH (1) PH12019501606A1 (https=)
PL (1) PL3565551T3 (https=)
PT (1) PT3565551T (https=)
SG (1) SG11201906226YA (https=)
WO (1) WO2018129479A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7436206B2 (ja) 2017-01-09 2024-02-21 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症を処置する方法
US11376237B2 (en) 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections
WO2022026993A1 (en) * 2020-07-27 2022-02-03 Northwestern University Antimicrobial choice algorithm for urinary tract infections
WO2024018372A2 (en) * 2022-07-20 2024-01-25 Sri Sathya Sai Institute Of Higher Learning A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy
CN121419770A (zh) * 2023-05-02 2026-01-27 希普拉有限公司 包含抗细菌剂的药物组合及其组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN105393011A (zh) * 2013-05-15 2016-03-09 舍弗勒技术股份两合公司 减少阻力的离合器板
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
JP7436206B2 (ja) 2017-01-09 2024-02-21 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症を処置する方法

Also Published As

Publication number Publication date
KR102768209B1 (ko) 2025-02-18
US20190336475A1 (en) 2019-11-07
NZ755141A (en) 2023-01-27
MX2022001704A (es) 2022-03-11
EP3565551A4 (en) 2020-09-23
JP2020504154A (ja) 2020-02-06
SG11201906226YA (en) 2019-08-27
US12478606B2 (en) 2025-11-25
MX390529B (es) 2025-03-20
CL2020001886A1 (es) 2020-12-18
PH12019501606A1 (en) 2020-06-15
PL3565551T3 (pl) 2024-09-23
WO2018129479A1 (en) 2018-07-12
AU2018205327B2 (en) 2023-11-30
KR20240133785A (ko) 2024-09-04
CN110402139A (zh) 2019-11-01
BR112019014089A2 (pt) 2020-02-04
JP2023012538A (ja) 2023-01-25
CO2019008575A2 (es) 2019-08-30
FI3565551T3 (fi) 2024-06-18
DK3565551T3 (da) 2024-06-17
CA3048650A1 (en) 2018-07-12
ES2979266T3 (es) 2024-09-25
HUE066805T2 (hu) 2024-09-28
AU2018205327A1 (en) 2019-07-25
KR20190104385A (ko) 2019-09-09
EP3565551A1 (en) 2019-11-13
JP7436206B2 (ja) 2024-02-21
MX2019008281A (es) 2019-12-02
PT3565551T (pt) 2024-06-14
EP4212157A1 (en) 2023-07-19
EP3565551B1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
CL2019001918A1 (es) Métodos para tratar infecciones bacterianas.
MX2016009898A (es) Tratamientos para acne resistente.
MX2024009339A (es) Biomarcadores utiles en el diagnostico de infecciones bacterianas y virales.
TW201613575A (en) Treatment of polybacterial infections
MX359921B (es) Métodos de tratamiento tópico para infecciones microbianas.
MX376691B (es) Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
BR112015013123A2 (pt) inibidores de beta-lactamase
ZA202002093B (en) Antibacterial compounds
MX2018002067A (es) Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
PH12017501300A1 (en) Novel iodophor composition and methods of use
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
ZA202006612B (en) Antibacterial compounds
WO2018094023A3 (en) Cyclic dipeptides and wound healing
MX2017002385A (es) Metodos y reactivos para la prevencion y/o el tratamiento de infecciones.
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
CR10023A (es) Métodos para tratar infecciones del tracto gastrointestinal con tigeciclina
MX2024008221A (es) Composicion que comprende glutation para usarse en inhibir o reducir el crecimiento de bacterias de un aislado clinico.
EA201791051A1 (ru) Способ лечения, профилактики или снижения риска возникновения кожной инфекции
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
BR112021018611A2 (pt) Anticorpos tendo especificidade para btn2 e usos dos mesmos
MX2018000384A (es) Composiciones para el tratamiento contra infecciones.
EP3538094A4 (en) FORMULATIONS, METHODS, KIT AND PHARMACEUTICAL FORMS FOR TREATING BACTERIAL INFECTIONS